Orthocell Ltd (ASX: OCC) Share Price and News

Price

$1.38

Movement

0.025 (-1.78%)

as at 9 May - Closed (20 mins delayed)

52 Week Range

$0.35 - $1.79

 
1 Year Return

+272.97%

Orthocell Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $333.93 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 241.98 million
Earnings per share -0.016
Dividend per share N/A
Year To Date Return 3.69%
Earnings Yield N/A
Franking -
Share Price

$1.38

Day Change

0.025 (-1.78%)

52 Week Range

$0.35 - $1.79

Yesterday's Close

$1.405

Today's Open

$1.47

Days Range

$1.37 - $1.51

Volume

1,918,628

Avg. Volume (1 month)

1,745,163

Turnover

$2,738,511

as at 9 May - Closed

Orthocell Ltd (ASX: OCC)
Latest News

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Share Gainers

Why Cedar Woods, Orthocell, PEXA, and St Barbara shares are storming higher today

These shares are having a good session on hump day. But why?

Read more »

Rising share price chart.
Share Gainers

Why DroneShield, Lynas, Novonix, and Orthocell shares are storming higher today

These shares are starting the week with a bang. Let's find out why.

Read more »

Rising share price chart.
Share Gainers

Why Orthocell, Paladin Energy, Telix, and Woodside shares are racing higher today

These shares are having a stronger day than most. But why?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Why FDA approval could turn this ASX All Ords company into a multibagger

Despite surging more than 230% in the past year, this company might be on its way to becoming a much…

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why Ansell, Capricorn Metals, Orthocell, and Sonic Healthcare shares are charging higher

These shares are ending the week on a positive note. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This company has entered a trading halt, is it about to announce FDA approval?

This regenerative medicine company is up more than 260% in the last year.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why A2 Milk, Orthocell, QBE, and Ramelius shares are pushing higher today

These shares are having a strong finish to the week. But why?

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Clinuvel, Orthocell, Vulcan, and Wildcat shares are storming higher

These shares are having a good time on hump day. But why?

Read more »

Person pointing finger on on an increasing graph which represents a rising share price.
Share Gainers

Why Clarity, New Hope, Orthocell, and West African shares are charging higher today

These shares are having a better day than most on Tuesday.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Up 290% in 12 months: Why this ASX healthcare stock is surging again today

This stock is continuing its ascent on Tuesday. But why?

Read more »

OCC ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
9th May 2025 2025-05-09T08:58:21 12 Distributors Signed for Remplir Covering 21 States in USYesNo8:58am3174k
30th Apr 2025 2025-04-30T09:08:23 Remplir Approved to Commence Sales in US$75m Canadian MarketYesNo9:08am3221k
29th Apr 2025 2025-04-29T11:52:42 Replacement Trading HaltYesNo11:52am3237k
29th Apr 2025 2025-04-29T11:23:02 Trading HaltYesNo11:23am3237k
29th Apr 2025 2025-04-29T11:04:07 Pause in TradingYesNo11:04am1115k
28th Apr 2025 2025-04-28T08:55:50 Remplir Approved to Commence Sales in US$84M Thai MarketYesNo8:55am3216k
23rd Apr 2025 2025-04-23T09:41:51 First US Distributors Signed for Remplirs US$1.6B marketYesNo9:41am3161k
14th Apr 2025 2025-04-14T08:52:43 Quarterly Activity Report & Appendix 4CYesNo8:52am10698k
10th Apr 2025 2025-04-10T09:00:24 Remplir Regulatory Application Submitted for Hong KongYesNo9:00am2175k
9th Apr 2025 2025-04-09T09:19:52 Regulatory Approval for Striate in US$65M Brazilian MarketYesNo9:19am3224k

About Orthocell Ltd

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialization of biological medical devices, cell therapies, and related technologies to address unmet clinical needs in human health in the regenerative medicine industry. Its product includes Striate plus; Remplir which is a collagen wrap used in peripheral nerve repair; and OrthoACI an implantation used for the treatment of articular cartilage defects in the knee and ankle. It also has various other products in its pipeline such as Tendon Cell Therapy and Collagen Medical Device Platform.

OCC Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
09 May 2025 $1.38 $-0.03 -2.14% 1,918,628 $1.47 $1.51 $1.37
08 May 2025 $1.41 $-0.08 -5.41% 1,025,936 $1.46 $1.47 $1.41
07 May 2025 $1.48 $-0.07 -4.52% 958,360 $1.56 $1.56 $1.47
06 May 2025 $1.55 $-0.04 -2.52% 607,854 $1.56 $1.61 $1.53
05 May 2025 $1.59 $-0.01 -0.63% 867,377 $1.60 $1.62 $1.52
02 May 2025 $1.60 $0.03 1.90% 1,440,759 $1.59 $1.67 $1.55
01 May 2025 $1.58 $-0.02 -1.25% 1,165,614 $1.64 $1.64 $1.56
30 Apr 2025 $1.60 $0.13 8.87% 4,757,771 $1.50 $1.70 $1.43
29 Apr 2025 $1.47 $0.07 5.00% 634,121 $1.40 $1.47 $1.35
28 Apr 2025 $1.40 $0.11 8.53% 2,611,042 $1.33 $1.46 $1.30
24 Apr 2025 $1.29 $0.04 3.20% 1,597,331 $1.28 $1.34 $1.26
23 Apr 2025 $1.25 $0.08 6.81% 2,616,939 $1.29 $1.29 $1.22
22 Apr 2025 $1.18 $-0.12 -9.27% 3,063,650 $1.28 $1.28 $1.16
17 Apr 2025 $1.30 $-0.06 -4.43% 1,378,664 $1.34 $1.34 $1.28
16 Apr 2025 $1.36 $-0.10 -6.90% 1,322,899 $1.44 $1.46 $1.34
15 Apr 2025 $1.45 $-0.03 -2.03% 1,134,224 $1.48 $1.52 $1.44
14 Apr 2025 $1.48 $0.06 4.23% 1,518,716 $1.45 $1.50 $1.39
11 Apr 2025 $1.42 $-0.08 -5.33% 1,022,172 $1.47 $1.48 $1.40
10 Apr 2025 $1.50 $0.25 19.92% 3,789,761 $1.39 $1.52 $1.39

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
03 Dec 2024 John Wielen Transfer 75,000 $66,000
Off-market transfer. Assuming off market transfer of shares
03 Dec 2024 John Wielen Transfer 75,000 $66,000
Off-market transfer. Assuming off market transfer of shares
03 Dec 2024 John Wielen Issued 166,666 $99,999
Placement.
29 Nov 2024 Paul Anderson Issued 2,148,088 $1,739,951
Issue of securities. 2,148,088 Rights
15 Oct 2024 Paul Anderson Buy 268,089 $195,704
Exercise of options. Cashless exercise of Unlisted Options.
15 Oct 2024 Paul Anderson Exercise 5,200,000 $3,796,000
Exercise of options. Cashless exercise of Unlisted Options.
15 Oct 2024 Paul Anderson Buy 80,426 $58,710
Exercise of options.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Professor Fiona Melanie Wood Non-Executive Director Nov 2023
Professor Wood has over 30 years of experience as a plastic and reconstructive surgeon. Professor Wood is currently a Consultant Plastic Surgeon at Fiona Stanley Hospital and Perth Children's Hospital, and the Winthrop Professor of Surgery at the University of Western Australia.
Mr Paul Frederick Anderson Chief Executive OfficerManaging Director Mar 2006
Mr Anderson has over 20 years of experience in the medical device and regenerative medicine fields with expertise in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has expertise in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings.
Dr Ravi Thadhani Non-Executive Director Mar 2023
Dr Thadhani is an Independent Non-Executive director of Orthocell who has co-authored more than 300 scientific publications, including articles in medical journals. Dr Thadhani has more than 30 years as a general and specialised physician, researcher, medical administrator and commercialisation adviser and has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. Dr Thadhani has served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors and has acted as expert advisor to multiple global pharmaceutical companies including Sandoz, Shore, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring.
Mr John Van Der Wielen Non-Executive ChairmanNon-Executive Director Jun 2023
Mr Wielen has over 30 years in wealth management, private banking, investments, and insurance, which includes executive positions in global financial services groups. These positions allowed Wielen to work in London, Luxemburg, Malaysia, Sydney and Perth, for brands such as Crown Resorts, Blackstone, HBF Health Ltd, Lloyds Banking Group, Lombard Assurance and ANZ Bank. Wielen currently holds the role of Chair, Crown Perth and is a Non-Executive Director on the Blackstone owned Crown Resorts Australia Ltd.
Hon Kim Beazley AC Non-Executive Director Jan 2024
Mr Beazley is an Independent Non-Executive director of Orthocell. Prior to this, Mr Beazley dedicated almost three decades to a career in Federal Parliament, representing the WA seats of Brand and Swan. Beazley held ministerial roles including Defence and Finance and served as Deputy Prime Minister and Leader of the Opposition. His parliamentary experience included committees on Intelligence, Foreign Affairs, Defence, and Trade.
Mr Peter Webse Company Secretary Mar 2023
-
Peter Webse Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Ming Hao Zheng & Fan Ying 6,805,886 3.25%
Mr Paul Frederick Anderson & Ms Nicole Jane Telford 6,233,335 2.97%
Mr Qixiao Zhou 5,996,241 2.86%
Mr Jia Xun Xu 5,014,107 2.39%
HSBC Custody Nominees (Australia) Limited 4,420,632 2.11%
Mr Patrick John McHale 4,300,000 2.05%
Wenola Pty Ltd 3,609,058 1.72%
Sankofa Strategic Equity Fund Limited 2,462,000 1.17%
Citicorp Nominees Pty Ltd 2,448,297 1.17%
The University of Western Australia 2,360,973 1.13%
Dr John Clifford Philpott & Mrs Rebecca Anne Philpott 2,048,677 0.98%
Sandini Pty Ltd 1,784,911 0.85%
Miss Kate Imogen Leaver 1,698,762 0.81%
Dr John Clifford Philpott 1,560,216 0.74%
Mr Tony Athas & Mrs Angela Athas 1,430,000 0.68%
Mr Vance Clark Moore 1,360,000 0.65%
Carjay Investments Pty Ltd 1,351,352 0.64%
Mr Bryan F Short 1,300,000 0.64%
Dr Russell Kay Hancock 1,200,000 0.57%
Aris Nominees Pty Ltd 1,042,816 0.50%

Profile

since

Note